GLP-1 drugs are the most significant health and wellness disruptor. Their efficacy, when it comes to weight loss, surpasses any historical solutions. But their power goes way beyond weight loss. GLP-1s are changing people’s lifestyles, behaviors and consumption habits. They are an economic engine.
Brands in nearly every business vertical will be impacted. In the US for example, with 1 in 8 Americans on a GLP-1, these drugs are already having a significant impact on brands across food & beverage, fashion, fitness, beauty, travel and retail. Analysts expect the global market value for GLP-1s to reach ~$500bn by 2030. This panel moderated by Brian Robinson, Global Chief Strategy Officer, Head of Growth and Havas’ GLP-1 Consultancy Lead, Havas Health Network with panelists Gerry Muhle, SVP & Head of Global Product Strategy, Galderma and Meredith Zapin, Regional VP, Sales - Travel, Health & Wellness, & Careers & Education, Microsoft Advertising explores the range of opportunities and potential risks that come with the GLP-1 disruption.